Taking advantage of mouse models and human CRC samples, they demonstrate that only KRAS mutant (KRAS*) CRCs exhibit gender differences, while KRAS-WT CRCs do not exhibit gender differences. This evidence concerns the gene KRAS and colorectal carcinoma.